ACT Genomics is Collaborating With Ignyta on Phase II STARTRK-2 Trial of Entrectinib


ACT Genomics has entered into a service agreement to screen patients for Ignyta, an oncology biotechnology company, who is enrolling all types of solid tumor patients harboring NTRK1,2,3/ROS1/ALK gene fusions into the phase II STARTRK-2 trial of entrectinib. ACT Genomics is the selected vendor in Taiwan to provide screening service in its CAP-accredited laboratory.

More info about Ignyta:

青娱极品盛宴国产分类-亚洲 欧美 日韩 国产 制服-国产爆乳合集在线视频,五月色婷婷,久久热在线视频,免费网站看v片在线薰衣草